Stock Market Update

[BRIEFING.COM] The S&P 500 (-0.5%), Nasdaq Composite (-0.5%), and DJIA (-1.3%) have settled into a firmly lower range an hour into the session.

The health care sector (-2.2%) is steadily moving lower pressured by considerable weakness in peer Novartis AG (NVS 139.05, -20.94, -13.09%) as primary-endpoint failures for pelacarsen and del-desiran, together with recent safety-related pauses involving rap-cel, trigger a broader reassessment of R&D productivity and pipeline value. The central issue is that several high-value programs have lost risk-adjusted value within days, even though NVS's formal medium-term sales outlook is unchanged. Pelacarsen's failure raises a fundamental target-validation question, while del-desiran's miss is particularly damaging because it was expected to validate the company's largest acquisition under CEO Vas Narasimhan. Secondary signals may justify further analysis, but overcoming a failed pivotal endpoint generally requires unusually strong, consistent evidence or another confirmatory study.

Amgen (AMGN 396.80, -40.43, -9.25%) remains the worst-performing S&P 500 component, and the iShares Biotechnology ETF is down 1.8%.